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Accumulating preclinical evidence suggests the use of amnion as a source of stem cells for
investigations of basic science concepts related to developmental cell biology, but also for
stem cells’ therapeutic applications in treating human disorders. We previously reported
isolation of viable rat amniotic fluid-derived stem (AFS) cells. Subsequently, we recently
reported the therapeutic benefits of intravenous transplantation of AFS cells in a rodent
model of ischemic stroke. Parallel lines of investigations have provided safety and efficacy
of stem cell therapy for treating stroke and other neurological disorders. This review article
highlights the need for investigations of mechanisms underlying AFS cells’ therapeutic
benefits and discusses lab-to-clinic translational gating items in an effort to optimize the
clinical application of the cell transplantation for stroke.
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WHY IS THERE A NEED FOR NOVEL TREATMENTS IN
STROKE?
Stroke, the fourthleading cause of death and the leading cause
of disability in the United States (Roger et al., 2012), has only
one FDA-approved drug, namely tissue plasminogen activator
(tPA). Due to tPA limitations and complications, which include
a limited therapeutic window (4.5 h from disease onset to tPA
administration) and adverse effects associated with delayed treat-
ment (i.e., hemorrhagic transformation), only a mere 3 percent of
ischemic stroke patients actually benefit from the tPA treatment
(Graham, 2003; Yip and Demaerschalk, 2007). This significant
unmet clinical need for stroke has prompted investigations to
increase the therapeutic window with innovative treatment strate-
gies specifically targeting the restorative phase, which begins days
to weeks post-stroke (Matsukawa et al., 2009; Yu et al., 2009;
Antonucci et al., 2011; Kaneko et al., 2011; Manuelpillai et al.,
2011).
DO STEM CELLS EXIST IN THE AMNION?
Stem cells have emerged as a prospective restorative agent for
stroke due to their ability to abrogate sub-acute and chronic
secondary cell death associated with the disease (Borlongan et al.,
1997; Nishino and Borlongan, 2000). We previously reported
the isolation of viable rat amniotic fluid-derived stem (AFS)
cells (Tajiri et al., 2012). Together with other research teams, the
grafted stem cells’ production of trophic factors and cytokines, as
well as the increase in levels of neurotrophic factors and reduced
inflammatory response in the ischemic stroke region, have been
directly attributed to the positive effects by transplantation of
AFS cells (Yu et al., 2009; Antonucci et al., 2011; Kaneko et al.,
2011; Manuelpillai et al., 2011). Furthermore, the inhibition of
apoptosis and oxidative stress, in tandem with stimulation of
angiogenesis, neurogenesis, and synaptogenesis, may be linked
as a benefit of AFS cells against stroke deficits (Yu et al., 2009;
Antonucci et al., 2011; Kaneko et al., 2011; Manuelpillai et al.,
2011). Even though stem cells can be harvested from various
sources (Borlongan et al., 2004, 2005; Hematti et al., 2004; Clavel
and Verfaillie, 2008; Burns et al., 2009; Ou et al., 2010), including
bone marrow, fetal and embryonic tissues, amnion-derived stem
cells are an appealing choice because of many logistical and ethical
advantages including the ease of isolation of the stem cells from
amnion tissue and the fluid (Yu et al., 2009; Antonucci et al., 2011;
Kaneko et al., 2011; Manuelpillai et al., 2011). Similar to amniotic-
tissue derived cells, the harvest of AFS cells poses negligible risk
of injury to the fetus. These cells are isolated from amniotic
fluid collected from amniocentesis, a pre-natal exam performed
at around 15–20 weeks of gestation. Accordingly, since AFS cells
can be isolated much earlier, compared to amniotic tissue-derived
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cells, AFS cells possess properties that closely resemble embryonic
and mesenchymal cell markers, which could be more beneficial
at treating diseases. The low immunogenicity, low tumorgenicity,
high proliferative capacity and anti-inflammatory characteristics,
are phenotypic features of transplantable cells (Newman et al.,
2005) that support AFS cells to be a safe and effective donor cell
for stroke (Yu et al., 2009; Antonucci et al., 2011; Kaneko et al.,
2011; Manuelpillai et al., 2011). Another distinguishing feature
of AFS cells when compared to amniotic tissue-derived cells is
the sterility involved. AFS cells are harvested via amniocentesis
under aseptic condition, but the sterility may be compromised
when stem cells are extracted from amnion tissue during child
delivery.
AFS cells can phenotypically commit to various lineages (Prusa
and Hengstschlager, 2002; In’t Anker et al., 2003; Prusa et al.,
2003; Fauza, 2004; Tsai et al., 2004, 2006; McLaughlin et al., 2006).
A misleading concept is the term “fluid” associated with AFS
cells because cells isolated during amniocentesis are comprised of
multiple stem cells originating from extra-embryonic and embry-
onic tissues (Prusa and Hengstschlager, 2002) and their properties
differ with gestational age (Yu et al., 2009; Antonucci et al., 2011;
Kaneko et al., 2011; Manuelpillai et al., 2011). Accordingly, phe-
notypic characterization of AFS cells reveal a plethora of stem cell
subtypes, from pluripotent embryonic stem cells to multipotent
adult stem cells owing likely to the age-dependent tissue plasticity
potential (De Coppi et al., 2007; Mauro et al., 2010). Indeed, AFS
cells from second trimester amniotic fluid display the ability to
differentiate into all three germ layers and express Oct-4, Nanog,
and SSEA-4 (Roubelakis et al., 2007), which are pluripotent
embryonic stem cell markers (Yu et al., 2009; Antonucci et al.,
2011; Kaneko et al., 2011; Manuelpillai et al., 2011). Although
considered as “adult stem cells”, the doubling time for the AFS
cells population is approximately 30–36 h with a high regen-
eration capacity that can be extended for over 250 doublings
without any measurable loss of chromosomal telomere length
(De Coppi et al., 2007). Altogether, these studies support the
amnion as a potent source of stem cells for investigations of basic
science concepts related to developmental cell biology, but also for
therapeutic purposes such as AFS cell transplantation for treating
human disorders, especially stroke.
ARE AFS CELLS TRANSPLANTABLE AND DO THEY EXERT
FUNCTIONAL BENEFITS?
The following protocol allows the isolation of AFS cells from
isolated amniotic fluid samples obtained from timed pregnant
Sprague-Dawley rats at gestation age 16–18 weeks (Tajiri et al.,
2012). For each sample, 2–3 ml of amniotic fluid, corresponding
to a cell number ranging from 2 × 103 to 2 × 106 are centrifuged
for 10 min at 1800 rpm. The high variance in the amount of cells
which can be isolated from amniotic fluid is influenced by factors
such as child birth, genetics, and fluid cell isolation. It is expected,
however, that these discrepancies can be overcome when technol-
ogy is able to be standardized with appropriate quality control
and assurance. This will yield a more accurate and efficient
cell isolation in the near future. Pellets are then resuspended in
Iscove’s modified Dulbecco’s medium supplemented with 20%
FBS, 100 U/ml penicillin, 100µg/ml streptomycin (Sigma), 2 mM
L-glutamine, 5 ng/ml basic fibroblast growth factor (FGF2) and
incubated at 37◦C with 5% humidified CO2. After 7 days, non-
adherent cells are removed and the adherent cells are allowed
to grow in the same medium, which is changed every 4 days.
When the cell culture reaches confluency (about 20 days after
the primary culture), cells are treated with 0.05% trypsin and
0.02% EDTA, then counted and replaced in 25 cm2 culture flasks.
For routine AFS cell procedure, an approximate yield of about
22 million stem cells per amnion fluid aspirate is anticipated.
The viability yield of AFS cells is about 70%, which would be
an estimated 15 million stem cells per amnion fluid aspirate.
An estimated range of several million AFS cells per milliliter of
amnion fluid are therefore expected to be obtained.
This protocol allows ample AFS cells for transplantation stud-
ies. Indeed, accumulating preclinical data have demonstrated the
potential of transplantation of AFS cells for treating experimental
models of brain diseases (Yu et al., 2009; Antonucci et al., 2011;
Kaneko et al., 2011; Manuelpillai et al., 2011). For example,
AFS cells are a potentially valuable source of stem cells to treat
Parkinson’s disease because under standard neuronal induction
protocols for stem cells, AFS cells preferentially differentiate
into a dopaminergic phenotype (Pisani et al., 2005). In parallel,
transplantation of AFS cells has been examined in stroke, with
AFS transplanted ischemic stroke mice exhibiting reduced short-
term memory impairment and improved sensorimotor ability,
somatosensory functions, and motor coordination (Rehni et al.,
2007). Although this study shows the beneficial effects of AFS cell
transplantation in experimental stroke, the mechanism underly-
ing the observed therapeutic benefits remained underexplored.
Perhaps AFS cells are mediating specific neurotransmitter release
to restore cellular function in an injured brain (Broughton et al.,
2013). This may explain a reversal of disease-induced impairment
of memory following AFS cell transplantation in an ischemic
model of stroke when transfer latency time (TLT) is used as a
parameter of memory. If administration of AFS cells following
middle cerebral artery occlusion and reperfusion significantly
attenuated ischemia-reperfusion induced increase in day 7 TLT,
it is likely that the AFS cells are secreting the neurotransmitters
necessary to ameliorate memory and subsequently, cognition in
general (Rehni et al., 2007).
HOW DO AFS CELLS AFFORD REPAIR OF THE STROKE BRAIN?
Our group transplanted AFS cells in experimental stroke ani-
mals (via occlusion of the middle cerebral artery; Borlongan
et al., 1998) using motor and cognitive tests, and subsequent
histological analysis of the brain to assess the mechanism of
action associated with AFS cell therapy for stroke. Although still
impaired compared to sham-operated animals (Acosta et al.,
2010), intravenous transplantation of AFS cells (1 million viable
cells) in adult Sprague-Dawley rats at 30 days after experimental
stroke revealed that motor and cognitive deficits were reduced at
60 days post-MCAo compared to vehicle-infused stroke animals
(Tajiri et al., 2012). Moreover, histological analyses revealed that
the AFS cell-transplanted stroke animals significantly decreased
infarct volumes by 92% compared to the vehicle-infused stroke
animals, which likely facilitated the recovery of motor and cog-
nitive functions. In addition, cell proliferation was significantly
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upregulated in the neurogenic subventrical zone of the AFS
cell-transplanted stroke animals compared to the vehicle-infused
stroke animals. In tandem, immature neuronal cells also increased
in the subventrical zone of AFS cell-transplanted stroke animals
compared to the vehicle-infused stroke animals. The increased
cell proliferation and reduced neuronal loss in the subventri-
cal zone was similarly observed in the dentate gyrus, another
major neurogenic niche. That AFS cell transplantation attenuated
stroke-induced behavioral and histological deficits coincided with
increased cell proliferation and neuronal differentiation in the two
neurogenic sites, namely subventricular zone and dentate gyrus,
implicates a major role of graft-induced host tissue repair in the
brain remodeling process following stroke (Table 1).
CANWE TRANSLATE AFS CELL GRAFT-MEDIATED
FUNCTIONAL RECOVERY IN EXPERIMENTAL STROKE
TO THE CLINIC?
Many stroke victims present with symptoms characterized by
sensorimotor and cognitive functions (Grefkes et al., 2008; Rush
et al., 2010; Lin et al., 2011). Up to now, most stroke animal
models have focused on motor impairments, disregarding the
cognitive declines that proceed after the brain offense (Borlongan,
2009; Chopp et al., 2009; STEPS, 2009). Findings on the pathol-
ogy of ischemic stroke support that secondary cell death may
extend beyond the routine cortical damage towards the hip-
pocampus, which is the key brain structure for learning and
memory consolidation (Scoville and Milner, 1957; Shors et al.,
2002; Saxe et al., 2006; Dupret et al., 2008). A decline in adult
neurogenesis is magnified during aging and correlates with wors-
ening of cognitive functions (McDonald and Wojtowicz, 2005;
Drapeau and Nora Abrous, 2008; Encinas et al., 2011).
Interestingly, the impaired neurogenesis and the cognitive decline
in the aging hippocampus (Freret et al., 2009; Dhawan et al., 2010;
Zvejniece et al., 2012) also accompany stroke (Dhawan et al., 2010;
Wattanathorn et al., 2011; Zvejniece et al., 2012).
Whereas our cognitive test results did not show any difference
in learning performance between the transplanted and vehicle-
infused stroke animals, the AFS cell-transplanted stroke animals
demonstrated a significantly improved reference memory com-
pared to the vehicle-infused stroke animals. This improvement
in the memory task directly correlates with increased neurogen-
esis in the hippocampus of AFS cell-transplanted stroke animals
relative to vehicle-infused stroke animals. In order to increase
the clinical relevance of cell therapy for stroke, especially when
evaluating cognitive deficits, is to employ a hippocampal depen-
dent task for spatial memory and reference memory (Gallagher
et al., 1993; Duva et al., 1997; Clarke et al., 1999; Anisman
and McIntyre, 2002; Broadbent et al., 2004; Clark et al., 2007;
Gillani et al., 2010; Bergado et al., 2011; Jurgens et al., 2012),
and long-term potentiation (Bliss and Collingridge, 1993; Norris
and Foster, 1999; Gusev and Alkon, 2001; Richardson et al.,
2002; Vorhees and Williams, 2006; Pisu et al., 2011; Xu et al.,
2012). Our data advanced the notion that transplanted AFS cells
selectively aid in the recovery of the reference memory, but not
task acquisition. Cognitive improvements in stem/progenitor cell
transplanted stroke animals have been linked previously with the
decline in cerebral infarct volumes (Nishino et al., 1993; Fukunaga
et al., 1999, 2003; Mimura et al., 2005), as well as reduced
secondary cell death loss in brain areas known to modulate motor
and cognitive functions (Ebrahimi et al., 1992; Pisani et al., 2005;
Takahashi et al., 2008; Tabuse et al., 2010; Miyoshi et al., 2012).
That the AFS cell transplanted stroke animals displayed improved
motor and cognitive performance, reduced the brain infarcts and
the secondary cell death, and enhanced the level of neurogenesis
provide insights on possible mechanisms of action underlying
Table 1 | Effects of AFS cells and amniotic tissue-derived cell in stroke-related disease.
Protective effects of AFS and amniotic tissue-derived stem Reference
cells in stroke-related disease
Stroke rats manifest a robust reduction of infarct volumes by 92% and reduced local
inflammation.
Liu et al. (2008), Tao et al. (2012) and Broughton et al.
(2013).
Cell proliferation, neuronal differentiation, and immature neuronal cells significantly
upregulated in the subventrical zone and dentate gyrus of stroke rats.
Ekdahl et al. (2009), Jezierski et al. (2010), Zhang et al.
(2010) and Prasongchean et al. (2012).
Reduced short term memory impairment and improved sensorimotor ability,
somatosensory functions, and motor coordination in stroke rats.
Rehni et al. (2007) and Broughton et al. (2013).
Ischemic rats present an increase of neurogenesis in the hippocampus, leading to
improved reference memory.
Tajiri et al. (2012).
Reversal of hemi-parkisonian syndrome and behavioral improvement thanks to the
formation of new dopaminergic fibers in the denervated striatum.
Sheng et al. (1993) and Bankiewicz et al. (1994).
Rats subjected to middle cerebral artery occlusion model express MAP2, Nestin, and glial
fibrillary acidic protein that improve behavioral recovery.
Liu et al. (2008) and Tao et al. (2012).
The administration of melatonin significantly increases the proliferation and survival of
human amniotic epithelial cells and boosts neuronal differentiation.
Kaneko et al. (2011).
Human amniotic membrane-derived mesenchymal stem cells lack major histocompatibility
complex class I molecule greatly reducing transplant rejection.
Tao et al. (2012) and Broughton et al. (2013).
Amniotic membrane mesenchymal stem cells have innate capacity to express factors for
endothelialization and angiogenesis. Crucial for wound recovery in ischemic diseases.
Warrier et al. (2012) and Broughton et al. (2013).
Amniotic membrane cell grafts enhance the recovery of cardiac function. Cargnoni et al. (2009).
A synopsis of the beneficial behavioral and cognitive effects observed in experimental animals models of stroke.
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the functional benefits afforded by AFS cell transplantation. Our
observed transplant-mediated recovery of motor and cognitive
functions confirms a recent report of AFS therapeutic effects in
stroke (Rehni et al., 2007), but our study expanded the short
timeline of 7 days from the previous study to 63 days.
The transplantation of AFS cells shows extensive therapeutic
benefits such as reduction in infarct volume, enhanced cell
proliferation, increased neuronal differentiation, and improved
memory and motor skills, seen with other stem cells (Yasuhara
et al., 2006a,b, 2008; Hara et al., 2007). The exact underlying
mechanism of these benefits is still unknown and understanding
therapeutic pathways could potentially yield promising insights
into optimizing AFS cell transplantation towards the clinical trial
stage. Clinical trials that closely reflect the preclinical data on
safety and efficacy of AFS cells in animal models of stroke will
enhance the functional outcome of this cell therapy in stroke
patients. Based on preclinical data demonstrating AFS cell safety
and efficacy, patients who suffer a stroke and show significant
inflammation of the brain or who display short-term memory
loss due to the accompanying injury to the hippocampus seem
to be the best candidates for future clinical trials of AFS cells.
Moreover, AFS cell therapy trials could be extended to patients
who have suffered from cardiac stroke, as animal models show
promising improvement in cardiac functions following AFS
cell transplantation (Bollini et al., 2011). In addition, a better
understanding of the mechanism(s) involved in the functional
improvement seen in transplanted stroke animals will likely
further optimize AFS cell therapy.
When contemplating with clinical applications of AFS cells,
the route of transplantation is key to successful outcomes of
targeted stroke patient population. Intracerebral (Rehni et al.,
2007; Liu et al., 2008), intraperitoneal (Ghionzoli et al., 2010),
and intravenous (Tajiri et al., 2012) have been explored in AFS
transplantation in experimental models of cerebral ischemia. The
intravenous route of transplantation is a minimally invasive pro-
cedure and poses less risk to the patient compared to intracerebral
transplantation. A peripheral injection method may be favored
over the direct transplantation route so that the stem cells can
be administered quickly after the onset of a stroke. A limited
FDA-approved clinical trial for intravenous transplantation of
placenta/amnion-derived stem cells in sub-acute stroke patients
was terminated with no available safety and efficacy results
(ClinicalTrials.gov., 2014).
The recommendations of Stem cell Therapeutics as an Emerg-
ing Paradigm for Stroke (STEPS; Borlongan, 2009; Chopp et al.,
2009; STEPS, 2009) are likely to facilitate the translational
research on AFS cell grafts for stroke. Such translational blueprint
for cell therapy in stroke provides important guidance in experi-
mental stroke testing and stem cell therapy, including the need for
multiple strains, both genders, and age groups to evaluate safety
and efficacy of AFS cells (Borlongan, 2009; Chopp et al., 2009;
STEPS, 2009). Equally important is the phenotypic characteri-
zation of AFS cells in order to allow replications of the results,
but also to maintain quality control and quality assurance of
the cells for transplantation therapy in the clinic. With this in
mind, another key component of translating laboratory studies
into clinical applications is to carefully and critically analyze the
type of transplantation procedure to be employed in the clinic.
The efficient isolation of AFS cells (i.e., during amniocentesis)
(Kalogiannidis et al., 2011) may prove applicable to allogenic
grafts in the stroke patients. The animal model shows the efficacy
of AFS cells 30 days after stroke, which suggests its beneficial
application to chronic stroke patients.
The collection of the AFS cells will likely require banking of
cells associated with storage costs that may not be covered by
health insurance. This will in turn require the donor to shoulder
the costs ranging to thousands of dollars. The studies conducted
so far exploring the immunogenic properties of human amniotic
cells have revealed that these cells inhibit the function of differ-
ent immune cells of the innate and adaptive immune response
(Borlongan et al., 1996; Insausti et al., 2014); however, it is also
documented that even autologous grafts have the potential to
elicit an immune response. Therefore, further investigations to
determine whether AFS cells are truly immune-free need to be
conducted. In addition, the heterogenic population of AFS cells
contains many cell phenotypes. While such variety of cell lineages
suggests differentiation capability of AFS cells to multiple cell
phenotypes and thus allowing many disease indications for AFS
cell therapy, the stability of phenotypic expression and functional
effects of AFS cells remain to be fully investigated. Altogether,
these challenges may seem to hinder translational potential of
AFS cells, but they pose as open avenues of research waiting to
be discovered towards realizing the full potential of AFS cells for
transplant therapy.
It is also important to discuss the practical issues associated
with stroke therapy in adults. The unpredictable occurrence of
a stroke event can be addressed by the ready availability of AFS
cells. However, the route of stem cell administration may be
dictated by the stroke disease phase. For example, acute stroke
will require rapid delivery of cells via minimally invasive route,
while chronic stroke may be amenable to intracerebral delivery
of the cells. In addition, the ready availability of the amnion
cells and timing of transplantation for both acute and chronic
phases of stroke will require cryopreserved cells, thereby requiring
high viability of cells following freezing and thawing storage. In
this case, a panel of cell release criteria monitoring high viability
of cells, normal karyotyping, and phenotypic stability (among
other cell quality assurance issues) need to be in place prior to
transplantation of AFS cells as these are common cell release
criteria in place for other donor stem cell types. Ultimately, the
maintenance of therapeutic efficacy due to scarce data to date
providing “efficacy” readout for cells prior to transplantation is a
challenge. A simple assay of neurotransmitter release or growth
factor secretion after thawing may need to be developed as an
efficacy release criterion which should enhance the therapeutic
outcome of AFS cell transplantation.
Transplanted AFS cells-induced cell proliferation, in tandem
with a decrease in neuronal loss, produced robust reduction in
cerebral infarcts (Tajiri et al., 2012). The subventricular zone and
dentate gyrus, two neurogenic niches in the brain, are critical to
the repair of damaged brain tissue (Ekdahl et al., 2009; Jezierski
et al., 2010; Zhang et al., 2010; Prasongchean et al., 2012). The
results imply that AFS cell transplantation may have enhanced
endogenous repair mechanisms by maximizing the potential of
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these two neurogenic sites to confer a host brain remodeling pro-
cess. Intravenous AFS cell transplantation in the chronic stage of
experimental stroke decreased motor and cognitive impairments,
maintained cell proliferation, and increased cell differentiation
in the host brain (Tajiri et al., 2012). The mechanism of action
appears to involve AFS grafted cells’ capacity to solicit endogenous
stem cells for brain repair. These observations offer insights into
therapeutic pathways of brain repair, and guide the design of
clinical trials of cell therapy in stroke.
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